

## Thomas Hughes, Ph.D.: Selected Publications

Deacon CF, **TE Hughes**, and JJ Holst. 1998. Dipeptidylpeptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anaesthetised pig. *Diabetes* 47: 764-769.

**Hughes TE**, MD Mone, ME Russell, SC Weldon, and EB Villhauer. 1999. NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. *Biochemistry* 38:11597-11603.

Coppola GM, Zhang YL, Schuster HF, Russell ME, **Hughes TE**. 2000. 1-aminomethylisoquinoline-4-carboxylates as novel dipeptidylpeptidase IV inhibitors. *Bioorg. Chem Lett.* 10:1555-1558.

Coppola GC, **Hughes TE**, Villhauer EB. DPP-IV Inhibition: Prospects as a Therapeutic Approach to Type 2 Diabetes. 2001 Annual Reports in Medicinal Chemistry 36:191-200.

Toft-Nielsen M-B, Damholt MB, Madsbad S, Hilsted LM, **Hughes TE**, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. *J. Clin. Endocrinol. Metab.* 2001; 86:3717-3723.

Deacon CF, Wamberg S, Bie P, **Hughes TE**, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. *J. Endocrinol.* 2002; 172:355-362.

Mitani H, Takimoto M, **Hughes TE**, Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity. *Jpn. J. Pharmacol.* 2002; 88:442-450.

Villhauer EB, Brinkman JB, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, **Hughes TE**. 1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino] acetyl-2-(S)-pyrrolidinecarbonitrile (NVP-DPP728): a Potent, Selective and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. *J. Med. Chem.* 2002;45:2362-2365.

Villhauer EB, Brinkman JB, Naderi GB, Burkey BF Dunning BE, Prasad K, Mangold BL, Russell ME, **Hughes TE**. 1-[[[3-Hydroxy-1-adamantyl]amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. *J. Med. Chem.* 2003; 46:2774-2789.

Valencia JV, Weldon SC, Quinn D, Kiers GH, DeGroot J, TeKoppele JM, **Hughes TE**. Advanced Glycation Endproduct ligands for the Receptor for Advanced Glycation Endproducts: Biochemical characterization and formation kinetics. *Anal. Biochem.* 2004; 324:68-78.

Valencia JV, Mone M, Zhang J, Weetall M, Buxton FP, **Hughes TE**. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. *Diabetes* 2004 53:743-51.

Valencia JV, Mone M, Koehne C, Rediske J, **Hughes TE**. Binding of Receptor for Advanced Glycation Endproducts (RAGE) ligands is not sufficient to induce inflammatory signals. Lack of activity of endotoxin-free albumin-derived advanced glycation endproducts. *Diabetologia* 2004 47:844-852.

Ahren B, **Hughes TE**. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. *Endocrinology* 2005; 146:2055-2059.

Ahren B, Sörhede Winzell M, Burkey B, **Hughes TE**. Beta-cell expression of a dominant-negative HNF-1 compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. *Eur. J. Pharmacol.* 2005; 521:164-168.

Burkey B, Wang PR, Bolognese L, Balkan B, Li X, Mone M, Russell M, **Hughes TE**. Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin Resistant Rats. *J. Pharmacol. Exp. Ther.* 2005; 315:688-695.

Gromada J and **Hughes TE**. Ringing the dinner bell for insulin: muscarinic M3 receptor activity in the control of pancreatic beta cell function. *Cell Metab* 2006; 3:390-392.